Doktor axborotnomasi 2024, №2 (114)
Subject of the article
ВИРУСНЫЙ ГЕПАТИТ В, СОВРЕМЕННЫЙ ВЗГЛЯДЫ, ДИАГНОСТИКА И ЛЕЧЕНИЕ (140-146)
Authors
З. К. Жумаева
Institution
Бухарский государственный медицинский институт, Бухара, Узбекистан
Abstract
Гепатит B — это воспалительное поражение печени (гепатоцитов), этиологическим агентом, который является вирус гепатита B. Болезнь протекает под острым (кратковременным и тяжелым) или хроническим (длительным) виде. Данный гепатит может переходить в хроническую форму с высоким риском летального исхода от цирроза и рака печени. В данной обзорной статьи приведены примеры по поводу изучения заболева ния который развивается после заражением вирусного гепатита В, что такой сам это вирус, его всемирное рас пространение, изучение его всех трёх антигенов, тактика лабораторной – серологической, иммунофермент ной, молекулярной диагностики, а также тактика введения и медикаментозное лечение больных с данной па тологией и главное профилактика вирусного гепатита В путём использования вакцин.
Key words
вирусный гепатит В, вакцинация по поводу гепатита, HbsAg, HbeAg, Anti-HBs, пег-ИФН-а, ламивудин, адефовирдипивоксил, телбивудин.
Literature
1. Abdul Basit S, Dawood A, Ryan J, Gish R. Tenofovir alafenamide for the treatment of chronic hepatitis B virus infection. Expert Rev Clin Pharmacol. 2017 Jul 03;10(7):707–716. 2. Agarwal K, Fung SK, Nguyen TT, Cheng W, Sicard E, Ryder SD, Flaherty JF, Lawson E, Zhao S, Subramanian GM, et al. Twentyeight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection. J Hepatol. 2015 Mar;62(3):533–540. 3. Aghasadeghi MR, Aghakhani A, Mamishi S, Bidari-Zerehpoosh F, Haghi Ashtiani MT, Sabeti S, Banifazl M, Karami A, Bavand A, Ramezani A. No evidence of occult HBV infection in population born after mass vaccina tion. Wien Med Wochenschr. 2020 Jun; 170(9–10):218–223. 4. Al-Qahtani AA, Al-Anazi MR, Nazir N, Abdo AA, Sanai FM, Al-Hamoudi WK, Alswat KA, Al-Ashgar HI, Khan MQ, Albenmousa A, et al. The correlation between hepatitis B virus Precore/core mutations and the progression of severe liver disease. Front Cell Infect Microbiol. 2018 Oct 22;8:355. 5. Al-Sadeq DW, Taleb SA, Zaied RE, Fahad SM, Smatti MK, Rizeq BR, Al Thani AA, Yassine HM, Nasrallah GK. Hepatitis B virus molecular epidemiology, host virus interaction, co infection, and laboratory diagnosis in the MENA Region: an Update. Pathogens. 2019 May 11;8(2):63. 6. Ambachew H, Zheng M, Pappoe F, Shen J, Xu Y. Genotyping and sero-virological characterization of hepatitis B virus (HBV) in blood donors, Southern Ethiopia. PLoS One. 2018 Feb 20;13(2):e0193177. 7. Arikan A, Şanlidağ T, Süer K, Sayan M, Akçali S, Güler E. [Molecular epidemiology of hepatitis B virus in North ern Cyprus] (in Turkish). Mikrobiyol Bul. 2016 Jan 7;50(1):86–93. 8. Arikan A, Sayan M, Sanlidag T, Suer K, Akcali S, Guvenir M. Evaluation of the pol/S gene overlapping mutations in chronic hepatitis B patients in Northern Cyprus. Pol J Microbiol. 2019 Sep; 68(3):317–322. 9. Arikan A, Sayan M. Comparison of Qiagen and Iontek hepatitis B virus DNA polymerase chain reaction quantifi cation kits in chronic hepatitis B patients infected with hepatitis B genotype D. Viral Hepat J. 2020 Apr 28;26(1):9–13. 10. Chan HL, Wang H, Niu J, Chim AM, Sung JJ. Two-year lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B: a double-blind, placebo-controlled trial. Antivir Ther. 2007;12(3): 345–353. 11. Cholongitas E, Haidich AB, Apostolidou-Kiouti F, Chalevas P, Papatheodoridis GV. Hepatitis B virus reactivation in HBsAg-negative, anti-HBc-positive patients receiving immunosuppressive therapy: a systematic review. Ann Gastroenterol. 2018;31(4):480–490. 12. Cooksley WGE, Piratvisuth T, Lee SD, Mahachai V, Chao YC, Tanwandee T, Chutaputti A, Chang WY, Zahm FE, Pluck N. Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat. 2003 Jul;10(4):298–305. 13. De Almeida RW, Espírito-Santo MP, Sousa PSF, de Almeida AJ, Lampe E, Lewis-Ximenez LL. Hepatitis B virus DNA stability in plasma samples under short-term storage at 42°C. Braz J Med Biol Res. 2015 Jun;48(6):553–556. 14. Dini G, Toletone A, Barberis I, Debarbieri N, Massa E, Paganino C, Bersi F, Montecucco A, Alicino C, Duran do P. Persistence of protective anti-HBs antibody levels and anamnestic response to HBV booster vaccination: A cross-sectional study among healthcare students 20 years following the universal immunization campaign in Italy. Hum Vaccin Immunother. 2017 Feb;13(2):440–444. 15. Dynavax. Hepatitis B Recombinant vaccine [Internet]. 2018 [cited 2018 Feb]. Available from https:// investors.dynavax.com/static-files/f93ec0ea-c184-4afb-b2d6-98ebd0030a79 16. EASL. HBV 2017 Clinical practice guidelines on the management of hepatitis B virus infection [Internet]. Geneva (Switzerland): European Association for the Study of the Liver; 2017 [cited 2020 Mar]. Available from https:// easl.eu/wp-content/uploads/2018/10/HepB-English-report.pdf 17. Fletcher GJ, Eapen CE, Abraham P. Hepatitis B genotyping: the utility for the clinicians. Indian J Gastroenterol. 2019 Oct 15;39(4): 315–320. https://doi.org/10.1007/s12664-019-00995-y 18. Ganczak M, Topczewska K, Budnik-Szymoniuk M, Korzeń M. Seroprevalence of anti-HBc, risk factors of occu pationally acquired HBV infection and HBV vaccination among hospital staff in Poland: a multicenter study. BMC Public Health. 2019 Dec;19(1):298. 19. Gilead Sciences. Prescribing information: VEMLIDY® (tenofovir alafenamide) [Internet]. Foster City (USA): Gilead Sciences; 2015 [cited 2020 Sep]. Available from https://www.gilead.com/-/media/files/pdfs/medicines/liver-disease/vemlidy/vemlidy_pi.pdf 20. Gilman C, Heller T, Koh C. Chronic hepatitis delta: A state-of-the-art review and new therapies. World J Gastro enterol. 2019 Aug 28; 25(32):4580–4597. 21. HBF. About the Hepatitis B Foundation. Doylestown (USA): Hepatitis B Foundation; 2018a [cited 2020 Sep 3]. Available fromhttps://www.hepb.org/assets/Uploads/About-the-Hepatitis-B-Foundation-Fact-Sheet-final-8-28 18.pdf 22. Ho EY, Yau T, Rousseau F, Heathcote EJ, Lau GKK. Preemptive adefovir versus lamivudine for prevention of hepatitis B reactivation in chronic hepatitis B patients undergoing chemotherapy. Hepatol Int. 2015 Apr;9(2):224 230. 23. Huang D, Lin T, Wang S, Cheng L, Xie L, Lu Y, Chen M, Zhu L, Shi J. The liver fibrosis index is superior to the APRI and FIB-4 for predicting liver fibrosis in chronic hepatitis B patients in China. BMC Infect Dis. 2019 Dec;19 (1):878. 24. Hyun Kim B, Ray Kim W. Epidemiology of hepatitis B virus infection in the United States. Clin Liver Dis (Hoboken). 2018 Jul;12(1): 1–4. 25. Innaimo SF, Seifer M, Bisacchi GS, Standring DN, Zahler R, Colonno RJ. Identification of BMS-200475 as a po tent and selective inhibitor of hepatitis B virus. Antimicrob Agents Chemother. 1997 Jul;41(7):1444–1448. 26. Jackson K, Locarnini S, Gish R. Diagnostics of Hepatitis B virus: standard of care and investigational. Clin Liver Dis (Hoboken). 2018 Jul;12(1):5–11. 27. Jefferies M, Rauff B, Rashid H, Lam T, Rafiq S. Update on global epidemiology of viral hepatitis and preventive strategies. World J Clin Cases. 2018 Nov 6;6(13):589–599. 28. Jeng WJ, Sheen IS, Liaw YF. Hepatitis B virus DNA level predicts hepatic decompensation in patients with acute exacerbation of chronic hepatitis B. Clin Gastroenterol Hepatol. 2010 Jun;8(6):541–545. 29. Kim H, Lee SA, Do SY, Kim BJ. Precore/core region mutations of hepatitis B virus related to clinical severity. World J Gastroenterol. 2016;22(17):4287–4296. 30. Kırdar S, Yaşa MH, Sayan M, Aydın N. [HBV pol/S gene mutations in chronic hepatitis B patients receiving nu cleoside/nucleotide analogues treatment] (in Turkish). Mikrobiyol Bul. 2019;53(2):144–155. 31. Kmet Lunacek N, Poljak M, Meglic-Volkar J, Rajter M, Prah J, Lesnicar G, Selic Kurincic T, Baklan Z, Remec T, Pal E, et al. Epidemiological, virological and clinical characteristics of hepatitis B virus genotypes in chronically infected persons in Slovenia. Hepat Mon. 2017 Mar 04;17(3):e43838. 32. Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, DeHertogh D, Wilber R, Zink RC, Cross A, et al.; BEHoLD AI463027 Study Group. Entecavir versus lamivudine for patients with HBeAg-negative chronic hep atitis B. N Engl J Med. 2006 Mar 09;354(10):1011–1020. 33. Liang TJ, Block TM, McMahon BJ, Ghany MG, Urban S, Guo JT, Locarnini S, Zoulim F, Chang KM, Lok AS. Present and future therapies of hepatitis B: from discovery to cure. Hepatology. 2015 Dec;62(6):1893–1908.